







Lab No. : BAR/25-02-2023/SR7338795

Patient Name : ANIMESH SARKAR Age : 35 Y 11 M 18 D

Gender: M

Lab Add. : Newtown, Kolkata-700156

Ref Dr.: Dr.MEDICAL OFFICER **Collection Date:** 25/Feb/2023 10:55AM

Report Date : 25/Feb/2023 04:03PM



		•		ETH: WYO.
Test Name	Result	Unit	Bio Ref. Interval	Method
UREA,BLOOD , GEL SERUM	23.5	mg/dL	19-49 mg/dL	Urease with GLDH
ALKALINE PHOSPHATASE , GEL SERE ALKALINE PHOSPHATASE	<i>UM</i> 63.00	U/L	46-116 U/L	IFCC standardization
BILIRUBIN (TOTAL), GEL SERUM BILIRUBIN (TOTAL)	0.70	mg/dL	0.3-1.2 mg/dL	Vanadate oxidation
SGOT/AST, GEL SERUM SGOT/AST	26.00	U/L	13-40 U/L	Modified IFCC
SODIUM, BLOOD , GEL SERUM SODIUM, BLOOD	140.00	mEq/L	132 - 146 mEq/L	ISE INDIRECT
*CHLORIDE, BLOOD , . CHLORIDE, BLOOD	104.00	mEq/L	99-109 mEq/L	ISE INDIRECT
CREATININE, BLOOD	1.08	mg/dL	0.7-1.3 mg/dL	Jaffe, alkaline picrate, kinetic
URIC ACID, BLOOD , GEL SERUM URIC ACID,BLOOD	7.00	mg/dL	3.5-7.2 mg/dL	Uricase/Peroxidase
BILIRUBIN (DIRECT), GEL SERUM BILIRUBIN (DIRECT)	0.10	mg/dL	<0.2 mg/dL	Vanadate oxidation
POTASSIUM, BLOOD , GEL SERUM POTASSIUM,BLOOD	4.40	mEq/L	3.5-5.5 mEq/L	ISE INDIRECT
GLUCOSE, FASTING , BLOOD, NAF PLA GLUCOSE, FASTING	<i>ASMA</i> 86	mg/dL	Impaired Fasting-100-125 .~Diabetes- >= 126.~Fasting defined as no caloric intake least 8 hours.	

 $In the absence of unequivocal \ hyperglycemia, \ diagnosis \ requires \ two \ abnormal \ test \ results \ from \ the \ same \ sample \ or \ in \ two \ separate \ test \ samples.$

Reference :

ADA Standards of Medical Care in Diabetes – 2020. Diabetes Care Volume 43, Supplement 1.

PHOSPHORUS-INORGANIC, BLOOD, GEL SERUM

PHOSPHORUS-INORGANIC,BLOOD 2.6 mg/dL 2.4-5.1 mg/dL Phosphomolybdate/UV









Lab No. : SR7338795 Name : ANIMESH SARKAR Age/G : 35 Y 11 M 18 D / M Date : 25-02-2023

Dr NEEPA CHOWDHURY MBBS MD (Biochemistry) Consultant Biochemist









Lab No. : SR7338795 Name	e : ANIMESH SARKAR		Age/G: 35 Y 11 M 18 D / M	Date: 25-02-2023
CALCIUM, BLOOD				
CALCIUM,BLOOD	9.40	mg/dL	8.7-10.4 mg/dL	Arsenazo III
SGPT/ALT, GEL SERUM				
SGPT/ALT	41.00	U/L	7-40 U/L	Modified IFCC
THYROID PANEL (T3, T4, TSH),	GEL SERUM			
T3-TOTAL (TRI IODOTHYRONIN	E) 1.21	ng/ml	0.60-1.81 ng/ml	CLIA
T4-TOTAL (THYROXINE)	8.4	μg/dL	3.2-12.6 µg/dL	CLIA
TSH (THYROID STIMULATING HO	ORMONE) 2.60	μIU/mL	0.55-4.78 μIU/mL	CLIA

Serum TSH levels exhibit a diurnal variation with the peak occurring during the night and the nadir, which approximates to 50% of the peak value, occurring between 1000 and 1600 hours.[1,2] References:

- 1. Bugalho MJ, Domingues RS, Pinto AC, Garrao A, Catarino AL, Ferreira T, Limbert E and Sobrinho L. Detection of thyroglobulin mRNA transcripts in peripheral blood of *individuals with and without thyroid glands: evidence for thyroglobulin expression by blood cells. Eur J Endocrinol* 2001;145:409-13.
- 2. Bellantone R, Lombardi CP, Bossola M, Ferrante A, Princi P, Boscherini M et al. Validity of thyroglobulin mRNA assay in peripheral blood of postoperative thyroid carcinoma patients in predicting tumor recurrence varies according to the histologic type: results of a prospective study. Cancer 2001;92:2273-9.

BIOLOGICAL REFERENCE INTERVAL: [ONLY FOR PREGNANT MOTHERS]

Trimester specific TSH LEVELS during pregnancy:

FIRST TRIMESTER: $0.10-3.00~\mu$ IU/mL SECOND TRIMESTER: 0.20 -3.50 μ IU/mL THIRD TRIMESTER : 0.30 -3.50 μ IU/mL

References:

- 1. Erik K. Alexander, Elizabeth N. Pearce, Gregory A. Brent, Rosalind S. Brown, Herbert Chen, Chrysoula Dosiou, William A. Grobman, Peter Laurberg, John H. Lazarus, Susan J. Mandel, Robin P. Peeters, and Scott Sullivan. Thyroid. Mar 2017.315-389. http://doi.org/10.1089/thy.2016.0457
- 2. Kalra S, Agarwal S, Aggarwal R, Ranabir S. Trimester-specific thyroid-stimulating hormone: An indian perspective. Indian J Endocr Metab 2018;22:1-4.

LIPID PROFILE, GEL SERUM

CHOLESTEROL-TOTAL	209.00	mg/dL	Desirable: < 200 mg/dL Borderline high: 200-239 mg/dL High: > or =240 mg/dL	Enzymatic
TRIGLYCERIDES	188.00	mg/dL	Normal:: < 150, BorderlineHigh::150-199, High:: 200-499, VeryHigh::>500	GPO-Trinder
HDL CHOLESTEROL	39.00	mg/dl	< 40 - Low 40-59- Optimum 60 - High	Elimination/catalase
LDL CHOLESTEROL DIRECT	167.0	mg/dL	OPTIMAL: <100 mg/dL, Near optimal/ above optimal: 100-129 mg/dL.	Elimination / Catalase

Borderline high: 130-159 mg/dL,

Lab No. : BAR/25-02-2023/SR7338795 Page 3 of 12









Lab No.: SR7338795 Name: ANIMESH SARKAR Age/G: 35 Y 11 M 18 D / M Date: 25-02-2023 High: 160-189 mg/dL, Very high: >=190 mg/dL VLDL 3 mg/dl < 40 mg/dl Calculated **CHOL HDL Ratio** 5.4 LOW RISK 3.3-4.4 AVERAGE Calculated RISK 4.47-7.1 MODERATE RISK

7.1-11.0 HIGH RISK >11.0

Reference: National Cholesterol Education Program. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on detection,

TOTAL PROTEIN [BLOOD] ALB:GLO RATIO , .

TOTAL PROTEIN	7.10	g/dL	5.7-8.2 g/dL	BIURET METHOD
ALBUMIN	4.7	g/dL	3.2-4.8 g/dL	BCG Dye Binding
GLOBULIN	2.40	g/dl	1.8-3.2 g/dl	Calculated
AG Ratio	1.96		1.0 - 2.5	Calculated

evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. May 16 2001;285(19):2486-97.

П

Dr. SUPARBA CHAKRABARTI MBBS, MD(BIOCHEMISTRY) Consultant Biochemist









Page 5 of 12

Lab No. : SR7338795 Name	: ANIMESH SARKAR		Age/G: 35 Y 11 M 18 D / M	Date: 25-02-2023
CBC WITH PLATELET & RETICULO	OCYTE COUNT , EDTA WHO	OLE BLOOD		
HEMOGLOBIN	15.6	g/dL	13 - 17	PHOTOMETRIC
WBC	8.2	*10^3/µL	4 - 10	DC detection method
RBC	5.34	*10^6/µL	4.5 - 5.5	DC detection method
PLATELET (THROMBOCYTE) COL	JNT 165	*10^3/µL	150 - 450*10^3/μL	DC detection method/Microscopy
DI FFERENTI AL COUNT				
NEUTROPHILS	62	%	40 - 80 %	Flowcytometry/Microscopy
LYMPHOCYTES	29	%	20 - 40 %	Flowcytometry/Microscopy
MONOCYTES	05	%	2 - 10 %	Flowcytometry/Microscopy
EOSINOPHILS	04	%	1-6%	Flowcytometry/Microscopy
BASOPHILS	00	%	0-0.9%	Flowcytometry/Microscopy
CBC SUBGROUP 1				
HEMATOCRIT / PCV	43.3	%	40 - 50 %	Calculated
MCV	81.1	fl	83 - 101 fl	Calculated
MCH	29.2	pg	27 - 32 pg	Calculated
MCHC	36.1	gm/dl	31.5-34.5 gm/dl	Calculated
RDW - RED CELL DISTRIBUTION	WIDTH 14.8	%	11.6-14%	Calculated
RETICULOCYTE COUNT- AUTOMATED,BLOOD	0.9	%	0.5-2.5%	Cell Counter/Microscopy
BLOOD GROUP ABO+RH [GEL M	ETHOD] , EDTA WHOLE BL	.OOD		
ABO	В			Gel Card
RH	POSITIVE			Gel Card

TECHNOLOGY USED: GEL METHOD

ADVANTAGES:

- · Gel card allows simultaneous forward and reverse grouping.
- · Card is scanned and record is preserved for future reference.
- Allows identification of Bombay blood group.
- Daily quality controls are run allowing accurate monitoring.

Historical records check not performed.

ESR (ERYTHROCYTE SEDIMENTATION RATE), EDTA WHOLE BLOOD

1stHour 05 mm/hr **0.00 - 20.00** mm/hr **Westergren**

URINE ROUTINE ALL, ALL, URINE

PHYSI CAL EXAMINATION

COLOUR PALE YELLOW
APPEARANCE SLIGHTLY HAZY

CHEMI CAL EXAMINATION

5.0 4.6 - 8.0 Dipstick (triple indicator method) рΗ SPECIFIC GRAVITY 1.020 1.005 - 1.030 Dipstick (ion concentration method) PROTEIN NOT DETECTED NOT DETECTED Dipstick (protein error of pH indicators)/Manual **GLUCOSE** NOT DETECTED NOT DETECTED Dipstick(glucose-oxidase-peroxidase method)/Manual KETONES (ACETOACETIC ACID, NOT DETECTED Dipstick (Legals test)/Manual NOT DETECTED ACETONE) NOT DETECTED NOT DETECTED Dipstick (pseudoperoxidase reaction) BLOOD **NEGATIVE** Dipstick (azo-diazo reaction)/Manual **BILIRUBIN NEGATIVE**









Lab No. : SR7338795	Name: ANIMESH SARKAR		Age/G: 35 Y 11 M 18 D / M	Date: 25-02-2023
UROBILINOGEN	NEGATIVE		NEGATIVE	Dipstick (diazonium ion reaction)/Manual
NITRITE	NEGATIVE		NEGATIVE	Dipstick (Griess test)
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	Dipstick (ester hydrolysis reaction)
MI CROSCOPI C EXAMI N	<u>IATI ON</u>			
LEUKOCYTES (PUS CELLS	0-1	/hpf	0-5	Microscopy
EPITHELIAL CELLS	0-1	/hpf	0-5	Microscopy
RED BLOOD CELLS	NOT DETECTED	/hpf	0-2	Microscopy
CAST	NOT DETECTED		NOT DETECTED	Microscopy
CRYSTALS	NOT DETECTED		NOT DETECTED	Microscopy
BACTERIA	NOT DETECTED		NOT DETECTED	Microscopy
YEAST	NOT DETECTED		NOT DETECTED	Microscopy

Note:

- 1. All urine samples are checked for adequacy and suitability before examination.
- 2. Analysis by urine analyzer of dipstick is based on reflectance photometry principle. Abnormal results of chemical examinations are confirmed by manual methods.
- 3. The first voided morning clean-catch midstream urine sample is the specimen of choice for chemical and microscopic analysis.
- 4. Negative nitrite test does not exclude urinary tract infections.
- 5. Trace proteinuria can be seen in many physiological conditions like exercise, pregnancy, prolonged recumbency etc.
- 6. False positive results for glucose, protein, nitrite, urobilinogen, bilirubin can occur due to use of certain drugs, therapeutic dyes, ascorbic acid, cleaning agents used in urine collection container.
- 7. Discrepancy between results of leukocyte esterase and blood obtained by chemical methods with corresponding pus cell and red blood cell count by microscopy can occur due to cell lysis.
- 8. Contamination from perineum and vaginal discharge should be avoided during collection, which may falsely elevate epithelial cell count and show presence of bacteria and/or yeast in the urine.

Dr. PANKTI PATEL MBBS , MD (PATHOLOGY) CONSULTANT PATHOLOGIST

Page 6 of 12









Page 7 of 12

Lab No.: SR7338795 Name: ANIMESH SARKAR Age/G: 35 Y 11 M 18 D / M Date: 25-02-2023

URIC ACID, URINE, SPOT URINE

URIC ACID, SPOT URINE 70.00 mg/dL 37-92 mg/dL URICASE

GLUCOSE, PP, BLOOD, NAF PLASMA

GLUCOSE,PP 93 mg/dL Impaired Glucose Tolerance-140 Gluc Oxidase Trinder

to 199.

Diabetes>= 200.

The test should be performed as described by the WHO, using a glucose load containing the equivalent of 75-g anhydrous glucose dissolved in water. In the absence of unequivocal hyperglycemia, diagnosis requires two abnormal test results from the same sample or in two separate test samples.

Reference

ADA Standards of Medical Care in Diabetes - 2020. Diabetes Care Volume 43, Supplement 1.

PDF Attached

GLYCATED HAEMOGLOBIN (HBA1C), EDTA WHOLE BLOOD

GLYCATED HEMOGLOBIN (HBA1C) 5.6 %

***FOR BIOLOGICAL REFERENCE INTERVAL DETAILS , PLEASE REFER TO THE BELOW MENTIONED REMARKS/NOTE WITH ADDITIONAL CLINICAL

ADDITIONAL CLINIC INFORMATION ***

HbA1c (IFCC) 38.0 mmol/mol HPLC

Clinical Information and Laboratory clinical interpretation on Biological Reference Interval:

Analyzer used: Bio-Rad-VARIANT TURBO 2.0

Method: HPLC Cation Exchange

Recommendations for glycemic targets

Ø Patients should use self-monitoring of blood glucose (SMBG) and HbA1c levels to assess glycemic control.

Ø The timing and frequency of SMBG should be tailored based on patients' individual treatment, needs, and goals.

- Ø Patients should undergo HbA1c testing at least twice a year if they are meeting treatment goals and have stable glycemic control.
- Ø If a patient changes treatment plans or does not meet his or her glycemic goals, HbA1c testing should be done quarterly.
- \varnothing For most adults who are not pregnant, HbA1c levels should be <7% to help reduce microvascular complications and macrovascular disease . Action suggested >8% as it indicates poor control.
- Ø Some patients may benefit from HbA1c goals that are stringent.

Result alterations in the estimation has been established in many circumstances, such as after acute/ chronic blood loss, for example, after surgery, blood transfusions, hemolytic anemia, or high erythrocyte turnover; vitamin B_{12} / folate deficiency, presence of chronic renal or liver disease; after administration of high-dose vitamin E / C; or erythropoietin treatment.

Reference: Glycated hemoglobin monitoring BMJ 2006; 333;586-8

References:

1. Chamberlain JJ, Rhinehart AS, Shaefer CF, et al. Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes. Ann Intern Med. Published online 1 March 2016. doi:10.7326/M15-3016.

2. Mosca A, Goodall I, Hoshino T, Jeppsson JO, John WG, Little RR, Miedema K, Myers GL, Reinauer H, Sacks DB, Weykamp CW. International Federation of Clinical Chemistry and Laboratory Medicine, IFCC Scientific Division. Global standardization of glycated hemoglobin measurement: the position of the IFCC Working Group. Clin Chem Lab Med. 2007;45(8):1077-1080.









Lab No. : SR7338795 Name : ANIMESH SARKAR Age/G : 35 Y 11 M 18 D / M Date : 25-02-2023

DR. ANANNYA GHOSH MBBS, MD (Biochemistry)

Consultant Biochemist



Patient Name : ANIMESH SARKAR Ref Dr. : Dr.MEDICAL OFFICER

Age : 35 Y 11 M 18 D Collection Date:

Gender: M Report Date: 25/Feb/2023 04:45PM



ECHO CARDIOGRAPHY- PLAIN

M MODE DATA:

PARAMETER		
	TEST VALUE	NORMAL RANGE
Aortic root diameter	3.27	2.0 - 4.0cm
Left atrial diameter	3.09	2.0 - 4.0cm
RV internal diameter	1.30	0.6 - 2.3cm
IV septal thickness (diastole)	0.99	0.60 - 1.10cm
LV internal diameter (diastole)	5.39	3.50 - 5.60cm
Post wall thickness (diastole)	0.90	0.60 - 1.10cm
LV internal diameter (systole)	3.36	2.40 - 4.20cm
LV Ejection fraction	65 %	55 - 75%

1) Left Ventricle:

Cavity size and wall thickness: Within normal limits.

LV wall motion study: No regional wall motion abnormality.

Systolic function: Good.

Diastolic compliance : Adequate

2) Left Atrium:

Normal size, no mass in the appendage / body.

3) Right Ventricle and Right Atrium:

Normal size, good RV systolic function.

4) Mitral Valve:

Normal leaflets, good excursion, normal subvalvar apparatus.

Atrial regurgitation.

5) Aortic Valve:

Three cusps- no thickening, good systolic excursion.

Lab No. : BAR/25-02-2023/SR7338795 Page 9 of 12



Lab No. : BAR/25-02-2023/SR7338795

Patient Name : ANIMESH SARKAR

: 35 Y 11 M 18 D Age

Report Date : 25/Feb/2023 04:45PM Gender : M

Lab Add.

Ref Dr.

Collection Date:

: Dr.MEDICAL OFFICER

No significant regurgitation noted.

6) Tricuspid Valve:

Normal leaflets, normal sized annulus, no significant regurgitation.

7) Pulmonary Valve:

Normal cusps, good systolic excursion.

8) Ventricular Septum:

Intact.

9) Inter atrial septum:

Intact.

10) Pericardium:

No thickening, no effusion.

11)Others:

No intra-cardiac mass.

CONCLUSION:

Good left ventricular systolic function with adequate diastolic compliance.

No pulmonary arterial hypertension.

Department of Non-invasive

Cardiology

Page 10 of 12 Lab No. : BAR/25-02-2023/SR7338795



Lab No. : BAR/25-02-2023/SR7338795

Patient Name : ANIMESH SARKAR Ref Dr. : Dr.MEDICAL OFFICER

Age : 35 Y 11 M 18 D Collection Date:

Gender: M Report Date: 25/Feb/2023 05:00PM



DEPARTMENT OF CARDIOLOGY REPORT OF E.C.G.

Lab Add.

DATA

HEART RATE	:	83 bpm
PR INTERVAL	:	120 ms
QRS DURATION	:	102 ms
QT INTERVAL	:	330 ms
QTC INTERVAL	:	388 ms

AXIS

P WAVE	:	59 degree
QRS WAVE	:	49 degree
T WAVE	:	24 degree

IMPRESSION:

Sinus rhythm.

Normal ECG.

Dr. A C RAY
Department of Non-invasive
Cardiology

Page 11 of 12



Lab No. : BAR/25-02-2023/SR7338795

Patient Name : ANIMESH SARKAR Ref Dr. : Dr.MEDICAL OFFICER

Age : 35 Y 11 M 18 D Collection Date:

Gender: M **Report Date**: 25/Feb/2023 03:21PM



X-RAY REPORT OF CHEST (PA)

Lab Add.

FINDINGS:

No active lung parenchymal lesion is seen.

Both the hila are normal in size, density and position.

Mediastinum is in central position. Trachea is in midline.

Domes of diaphragm are smoothly outlined. Position is within normal limits.

Lateral costo-phrenic angles are clear.

The cardio-thoracic ratio is normal.

Bony thorax reveals no definite abnormality.

IMPRESSION:

Normal study.

Dr. Anoop Sastry
MBBS, DMRT(CAL)
CONSULTANT RADIOLOGIST
Registration No.: WB-36628

Lab No. : BAR/25-02-2023/SR7338795 Page 12 of 12

SURAKSHA DIAGNOSTIC, RAJARHAT, KOLKATA. BIO-RAD VARIANT TURBO CDM 5.4 s/n 15893

PATIENT REPORT V2TURBO_A1c_2.0

Patient Data Analysis Data

Sample ID: C02135002405 Analysis Performed: 25/FEB/2023 15:39:59

 Patient ID:
 SR7338795
 Injection Number:
 5009U

 Name:
 Run Number:
 106

 Physician:
 Rack ID:
 0003

 Sex:
 Tube Number:
 1

DOB: Report Generated: 25/FEB/2023 15:49:07

Operator ID: ASIT

Comments:

	NGSP		Retention	Peak
Peak Name	%	Area %	Time (min)	Area
A1a		0.9	0.155	15281
A1b		1.3	0.214	21950
F		0.7	0.267	12743
LA1c		1.7	0.392	30331
A1c	5.6		0.495	78796
P3		3.4	0.780	59837
P4		1.2	0.860	21659
Ao		86.2	0.994	1497028

Total Area: 1,737,624

<u>HbA1c (NGSP) = 5.6 %</u> HbA1c (IFCC) = 38 mmol/mol

